





【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																																																		
P	早期乳癌 乳房部分切除後				I	寡分割照射																																																																																														
C	通常分割照射				O	1. 同側乳房内再発（局所再発）割合の																																																																																														
研究デザイン		RCT			文献数		7																																																																																													
コード		Owen 2006, STARTA 2013, STARTB 2013, Whelan 2010, Zhao 2017, Wang 2020, Offersen 2020																																																																																																		
モデル		ランダム効果モデル			方法	Inverse-Variance法																																																																																														
効果指標		リスク比			統合値	0.94 (0.79-1.11), P = 0.46																																																																																														
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>Risk Ratio IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Owen 2006</td><td>108</td><td>940</td><td>50</td><td>470</td><td>29.9%</td><td>1.08 [0.79, 1.48]</td><td rowspan="7"></td></tr><tr><td>STARTA 2013</td><td>84</td><td>1487</td><td>40</td><td>749</td><td>22.4%</td><td>1.06 [0.73, 1.53]</td></tr><tr><td>STARTB 2013</td><td>36</td><td>1110</td><td>50</td><td>1105</td><td>17.0%</td><td>0.72 [0.47, 1.09]</td></tr><tr><td>Whelan 2010</td><td>41</td><td>622</td><td>42</td><td>612</td><td>17.4%</td><td>0.96 [0.63, 1.46]</td></tr><tr><td>Offersen 2020</td><td>20</td><td>917</td><td>27</td><td>937</td><td>9.2%</td><td>0.76 [0.43, 1.34]</td></tr><tr><td>Wang 2020</td><td>5</td><td>365</td><td>8</td><td>364</td><td>2.4%</td><td>0.62 [0.21, 1.89]</td></tr><tr><td>Zhao 2017</td><td>4</td><td>53</td><td>4</td><td>54</td><td>1.7%</td><td>1.02 [0.27, 3.86]</td></tr><tr><td>Total (95% CI)</td><td></td><td>5494</td><td></td><td>4291</td><td>100.0%</td><td>0.94 [0.79, 1.11]</td></tr><tr><td>Total events</td><td>298</td><td></td><td>221</td><td></td><td></td><td></td></tr><tr><td colspan="6">Heterogeneity: Tau² = 0.00; Chi² = 3.84, df = 6 (P = 0.70); I² = 0%</td><td></td></tr><tr><td colspan="6">Test for overall effect: Z = 0.73 (P = 0.46)</td><td></td></tr></tbody></table>						Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	Owen 2006	108	940	50	470	29.9%	1.08 [0.79, 1.48]		STARTA 2013	84	1487	40	749	22.4%	1.06 [0.73, 1.53]	STARTB 2013	36	1110	50	1105	17.0%	0.72 [0.47, 1.09]	Whelan 2010	41	622	42	612	17.4%	0.96 [0.63, 1.46]	Offersen 2020	20	917	27	937	9.2%	0.76 [0.43, 1.34]	Wang 2020	5	365	8	364	2.4%	0.62 [0.21, 1.89]	Zhao 2017	4	53	4	54	1.7%	1.02 [0.27, 3.86]	Total (95% CI)		5494		4291	100.0%	0.94 [0.79, 1.11]	Total events	298		221				Heterogeneity: Tau² = 0.00; Chi² = 3.84, df = 6 (P = 0.70); I² = 0%							Test for overall effect: Z = 0.73 (P = 0.46)							
		Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																											
			Events	Total	Events	Total		IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI																																																																																											
		Owen 2006	108	940	50	470	29.9%	1.08 [0.79, 1.48]																																																																																												
		STARTA 2013	84	1487	40	749	22.4%	1.06 [0.73, 1.53]																																																																																												
		STARTB 2013	36	1110	50	1105	17.0%	0.72 [0.47, 1.09]																																																																																												
		Whelan 2010	41	622	42	612	17.4%	0.96 [0.63, 1.46]																																																																																												
		Offersen 2020	20	917	27	937	9.2%	0.76 [0.43, 1.34]																																																																																												
		Wang 2020	5	365	8	364	2.4%	0.62 [0.21, 1.89]																																																																																												
		Zhao 2017	4	53	4	54	1.7%	1.02 [0.27, 3.86]																																																																																												
Total (95% CI)		5494		4291	100.0%	0.94 [0.79, 1.11]																																																																																														
Total events	298		221																																																																																																	
Heterogeneity: Tau² = 0.00; Chi² = 3.84, df = 6 (P = 0.70); I² = 0%																																																																																																				
Test for overall effect: Z = 0.73 (P = 0.46)																																																																																																				
コメント： 同側乳房内再発（局所再発）割合に有意差は検出されない。																																																																																																				
ファンネル プロット																																																																																																				
		コメント： 出版バイアスは認められない																																																																																																		
その他の解析							コメント：																																																																																													
メタリグ レッション																																																																																																				
感度分析																																																																																																				

【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																					
P	早期乳癌 乳房部分切除後		I	寡分割照射																																																			
C	通常分割照射		O	3. 全生存割合の低下																																																			
研究デザイン		RCT		文献数	6																																																		
コード		STARTA 2013, STARTB 2013, Wang 2020, Offersen 2020, Whelan2010, Zhao 2017																																																					
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																		
効果指標		ハザード比		統合値	0.92 (0.82- 1.04) P= 0.19																																																		
フォレスト プロット		<table><thead><tr><th>Study or Subgroup</th><th>log[Hazard Ratio]</th><th>SE</th><th>Weight</th><th>Hazard Ratio IV, Random, 95% CI</th></tr></thead><tbody><tr><td>STARTA 2013</td><td>0.01</td><td>0.1064</td><td>32.9%</td><td>1.01 [0.82, 1.24]</td></tr><tr><td>STARTB 2013</td><td>-0.2231</td><td>0.1059</td><td>33.2%</td><td>0.80 [0.65, 0.98]</td></tr><tr><td>Whelan 2010</td><td>-0.0619</td><td>0.129</td><td>22.4%</td><td>0.94 [0.73, 1.21]</td></tr><tr><td>Offersen 2020</td><td>-0.0202</td><td>0.2095</td><td>8.5%</td><td>0.98 [0.65, 1.48]</td></tr><tr><td>Wang 2020</td><td>0.1823</td><td>0.4467</td><td>1.9%</td><td>1.20 [0.50, 2.88]</td></tr><tr><td>Zhao 2017</td><td>0.1823</td><td>0.5605</td><td>1.2%</td><td>1.20 [0.40, 3.60]</td></tr><tr><td colspan="3">Total (95% CI)</td><td>100.0%</td><td>0.92 [0.82, 1.04]</td></tr><tr><td colspan="5">Heterogeneity: Tau² = 0.00; Chi² = 3.21, df = 5 (P = 0.67); I² = 0%</td></tr><tr><td colspan="5">Test for overall effect: Z = 1.32 (P = 0.19)</td></tr></tbody></table> 				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	STARTA 2013	0.01	0.1064	32.9%	1.01 [0.82, 1.24]	STARTB 2013	-0.2231	0.1059	33.2%	0.80 [0.65, 0.98]	Whelan 2010	-0.0619	0.129	22.4%	0.94 [0.73, 1.21]	Offersen 2020	-0.0202	0.2095	8.5%	0.98 [0.65, 1.48]	Wang 2020	0.1823	0.4467	1.9%	1.20 [0.50, 2.88]	Zhao 2017	0.1823	0.5605	1.2%	1.20 [0.40, 3.60]	Total (95% CI)			100.0%	0.92 [0.82, 1.04]	Heterogeneity: Tau ² = 0.00; Chi ² = 3.21, df = 5 (P = 0.67); I ² = 0%					Test for overall effect: Z = 1.32 (P = 0.19)				
		Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI																																																	
STARTA 2013	0.01	0.1064	32.9%	1.01 [0.82, 1.24]																																																			
STARTB 2013	-0.2231	0.1059	33.2%	0.80 [0.65, 0.98]																																																			
Whelan 2010	-0.0619	0.129	22.4%	0.94 [0.73, 1.21]																																																			
Offersen 2020	-0.0202	0.2095	8.5%	0.98 [0.65, 1.48]																																																			
Wang 2020	0.1823	0.4467	1.9%	1.20 [0.50, 2.88]																																																			
Zhao 2017	0.1823	0.5605	1.2%	1.20 [0.40, 3.60]																																																			
Total (95% CI)			100.0%	0.92 [0.82, 1.04]																																																			
Heterogeneity: Tau ² = 0.00; Chi ² = 3.21, df = 5 (P = 0.67); I ² = 0%																																																							
Test for overall effect: Z = 1.32 (P = 0.19)																																																							
コメント：全生存割合に有意差は認められない。																																																							
ファンネル プロット																																																							
		コメント：出版バイアスは認められない																																																					
その他の解析		コメント：																																																					
メタリ レシ ョ ン																																																							
感度分析																																																							



【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																							
P	早期乳癌 乳房部分切除後		I	寡分割照射																																					
C	通常分割照射		O	4. 無再発生存割合の低下																																					
研究デザイン		RCT	文献数		4																																				
コード		STARTA 2013, STARTB 2013, Whelan 2002, Wang 2020																																							
モデル		ランダム効果モデル	方法	Inverse-Variance法																																					
効果指標		ハザード比	統合値	0.99 (0.80-1.21) P= 0.90																																					
フォレスト プロット		<table><thead><tr><th>Study or Subgroup</th><th>log[Hazard Ratio]</th><th>SE</th><th>Weight</th><th>Hazard Ratio</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>STARTA 2013</td><td>0.0296</td><td>0.098</td><td>32.9%</td><td>1.03</td><td>[0.85, 1.25]</td></tr><tr><td>STARTB 2013</td><td>-0.2485</td><td>0.1009</td><td>32.3%</td><td>0.78</td><td>[0.64, 0.95]</td></tr><tr><td>Whelan 2002</td><td>0.1398</td><td>0.1542</td><td>23.0%</td><td>1.15</td><td>[0.85, 1.56]</td></tr><tr><td>Wang 2020</td><td>0.2151</td><td>0.2634</td><td>11.7%</td><td>1.24</td><td>[0.74, 2.08]</td></tr><tr><td colspan="3">Total (95% CI)</td><td>100.0%</td><td>0.99</td><td>[0.80, 1.21]</td></tr></tbody></table> Heterogeneity: Tau² = 0.02; Chi² = 7.06, df = 3 (P = 0.07); I² = 57% Test for overall effect: Z = 0.13 (P = 0.90) 				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio	IV, Random, 95% CI	STARTA 2013	0.0296	0.098	32.9%	1.03	[0.85, 1.25]	STARTB 2013	-0.2485	0.1009	32.3%	0.78	[0.64, 0.95]	Whelan 2002	0.1398	0.1542	23.0%	1.15	[0.85, 1.56]	Wang 2020	0.2151	0.2634	11.7%	1.24	[0.74, 2.08]	Total (95% CI)			100.0%	0.99	[0.80, 1.21]
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio	IV, Random, 95% CI																																				
STARTA 2013	0.0296	0.098	32.9%	1.03	[0.85, 1.25]																																				
STARTB 2013	-0.2485	0.1009	32.3%	0.78	[0.64, 0.95]																																				
Whelan 2002	0.1398	0.1542	23.0%	1.15	[0.85, 1.56]																																				
Wang 2020	0.2151	0.2634	11.7%	1.24	[0.74, 2.08]																																				
Total (95% CI)			100.0%	0.99	[0.80, 1.21]																																				
		コメント：無再発生存割合に有意差は認められない。																																							
ファンネル プロット																																									
		コメント：出版バイアスは認められない																																							
その他の解析				コメント：																																					
メタリ レシヨ ン																																									
感度分析																																									

【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																																															
P	早期乳癌 乳房部分切除後		I	寡分割照射																																																																																													
C	通常分割照射		O	5. 整容性の維持																																																																																													
研究デザイン		RCT		文献数	8																																																																																												
コード		Taher 2004, Yornold 2005, Whelan2010, Hou 2015, Shaitelman 2018, Wang 2020, Offersen 2020, Zhao 2017																																																																																															
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																																																												
効果指標		リスク比		統合値	0.94 (0.83-1.07) P = 0.37																																																																																												
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>Risk Ratio IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Yornold 2005</td><td>311</td><td>535</td><td>165</td><td>271</td><td>35.5%</td><td>0.95 [0.85, 1.08]</td><td rowspan="9"></td></tr><tr><td>Offersen 2020</td><td>153</td><td>825</td><td>193</td><td>812</td><td>24.2%</td><td>0.78 [0.65, 0.94]</td></tr><tr><td>Whelan 2010</td><td>71</td><td>235</td><td>62</td><td>216</td><td>14.3%</td><td>1.05 [0.79, 1.40]</td></tr><tr><td>Shaitelman 2018</td><td>34</td><td>96</td><td>32</td><td>111</td><td>8.6%</td><td>1.23 [0.83, 1.83]</td></tr><tr><td>Wang 2020</td><td>38</td><td>345</td><td>32</td><td>343</td><td>7.1%</td><td>1.18 [0.76, 1.84]</td></tr><tr><td>Zhao 2017</td><td>12</td><td>44</td><td>15</td><td>46</td><td>3.7%</td><td>0.84 [0.44, 1.58]</td></tr><tr><td>Hou 2015</td><td>13</td><td>40</td><td>11</td><td>40</td><td>3.4%</td><td>1.18 [0.60, 2.32]</td></tr><tr><td>Taher 2004</td><td>6</td><td>14</td><td>11</td><td>15</td><td>3.3%</td><td>0.58 [0.30, 1.15]</td></tr><tr><td>Total (95% CI)</td><td></td><td>2134</td><td></td><td>1854</td><td>100.0%</td><td>0.94 [0.83, 1.07]</td></tr><tr><td>Total events</td><td>638</td><td></td><td>521</td><td></td><td></td><td></td></tr><tr><td colspan="7">Heterogeneity: Tau² = 0.01; Chi² = 9.60, df = 7 (P = 0.21); I² = 27% Test for overall effect: Z = 0.90 (P = 0.37)</td></tr></tbody></table> コメント：全体を通じて寡分割照射は通常分割照射と同程度の成績であった。				Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	Yornold 2005	311	535	165	271	35.5%	0.95 [0.85, 1.08]		Offersen 2020	153	825	193	812	24.2%	0.78 [0.65, 0.94]	Whelan 2010	71	235	62	216	14.3%	1.05 [0.79, 1.40]	Shaitelman 2018	34	96	32	111	8.6%	1.23 [0.83, 1.83]	Wang 2020	38	345	32	343	7.1%	1.18 [0.76, 1.84]	Zhao 2017	12	44	15	46	3.7%	0.84 [0.44, 1.58]	Hou 2015	13	40	11	40	3.4%	1.18 [0.60, 2.32]	Taher 2004	6	14	11	15	3.3%	0.58 [0.30, 1.15]	Total (95% CI)		2134		1854	100.0%	0.94 [0.83, 1.07]	Total events	638		521				Heterogeneity: Tau ² = 0.01; Chi ² = 9.60, df = 7 (P = 0.21); I ² = 27% Test for overall effect: Z = 0.90 (P = 0.37)						
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																										
	Events	Total	Events	Total		IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI																																																																																										
Yornold 2005	311	535	165	271	35.5%	0.95 [0.85, 1.08]																																																																																											
Offersen 2020	153	825	193	812	24.2%	0.78 [0.65, 0.94]																																																																																											
Whelan 2010	71	235	62	216	14.3%	1.05 [0.79, 1.40]																																																																																											
Shaitelman 2018	34	96	32	111	8.6%	1.23 [0.83, 1.83]																																																																																											
Wang 2020	38	345	32	343	7.1%	1.18 [0.76, 1.84]																																																																																											
Zhao 2017	12	44	15	46	3.7%	0.84 [0.44, 1.58]																																																																																											
Hou 2015	13	40	11	40	3.4%	1.18 [0.60, 2.32]																																																																																											
Taher 2004	6	14	11	15	3.3%	0.58 [0.30, 1.15]																																																																																											
Total (95% CI)		2134		1854	100.0%	0.94 [0.83, 1.07]																																																																																											
Total events	638		521																																																																																														
Heterogeneity: Tau ² = 0.01; Chi ² = 9.60, df = 7 (P = 0.21); I ² = 27% Test for overall effect: Z = 0.90 (P = 0.37)																																																																																																	
ファンネル プロット		コメント：出版バイアスは認められない																																																																																															
その他の解析		コメント：																																																																																															
メタリグ レシヨ ン																																																																																																	
感度分析																																																																																																	

【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																	
P	早期乳癌 乳房部分切除後		I	寡分割照射																																																															
C	通常分割照射		O	6. 急性期有害事象の悪化(皮膚炎G2 or																																																															
研究デザイン		RCT		文献数	5																																																														
コード		Taher 2004, Shaitelman 2015, De Felice 2017, Hou 2015, Schmeel 2020																																																																	
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																														
効果指標		リスク比		統合値	0.55 (0.45-0.66) P < 0.00001																																																														
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th rowspan="2">Risk Ratio IV, Random, 95% CI</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th></tr></thead><tbody><tr><td>Shaitelman 2018</td><td>50</td><td>138</td><td>103</td><td>149</td><td>62.7%</td><td>0.52 [0.41, 0.67]</td></tr><tr><td>Schmeel 2020</td><td>19</td><td>70</td><td>30</td><td>70</td><td>17.2%</td><td>0.63 [0.40, 1.01]</td></tr><tr><td>De Felice 2017</td><td>9</td><td>58</td><td>25</td><td>62</td><td>8.4%</td><td>0.38 [0.20, 0.75]</td></tr><tr><td>Taher 2004</td><td>6</td><td>15</td><td>9</td><td>15</td><td>6.8%</td><td>0.67 [0.32, 1.40]</td></tr><tr><td>Hou 2015</td><td>7</td><td>40</td><td>9</td><td>40</td><td>4.8%</td><td>0.78 [0.32, 1.88]</td></tr><tr><td colspan="2">Total (95% CI)</td><td colspan="2">321</td><td colspan="2">336</td><td>100.0%</td><td>0.55 [0.45, 0.66]</td></tr><tr><td colspan="2">Total events</td><td colspan="2">91</td><td colspan="2">176</td><td colspan="2"></td></tr></tbody></table> Heterogeneity: Tau² = 0.00; Chi² = 2.42, df = 4 (P = 0.66); I² = 0% Test for overall effect: Z = 6.07 (P < 0.00001) 				Study or Subgroup	Experimental		Control		Weight	Risk Ratio IV, Random, 95% CI	Events	Total	Events	Total	Shaitelman 2018	50	138	103	149	62.7%	0.52 [0.41, 0.67]	Schmeel 2020	19	70	30	70	17.2%	0.63 [0.40, 1.01]	De Felice 2017	9	58	25	62	8.4%	0.38 [0.20, 0.75]	Taher 2004	6	15	9	15	6.8%	0.67 [0.32, 1.40]	Hou 2015	7	40	9	40	4.8%	0.78 [0.32, 1.88]	Total (95% CI)		321		336		100.0%	0.55 [0.45, 0.66]	Total events		91		176			
Study or Subgroup	Experimental		Control		Weight		Risk Ratio IV, Random, 95% CI																																																												
	Events	Total	Events	Total																																																															
Shaitelman 2018	50	138	103	149	62.7%	0.52 [0.41, 0.67]																																																													
Schmeel 2020	19	70	30	70	17.2%	0.63 [0.40, 1.01]																																																													
De Felice 2017	9	58	25	62	8.4%	0.38 [0.20, 0.75]																																																													
Taher 2004	6	15	9	15	6.8%	0.67 [0.32, 1.40]																																																													
Hou 2015	7	40	9	40	4.8%	0.78 [0.32, 1.88]																																																													
Total (95% CI)		321		336		100.0%	0.55 [0.45, 0.66]																																																												
Total events		91		176																																																															
		コメント：寡分割照射群で皮膚毒性が軽微な傾向があり、有意差が検出された。																																																																	
ファンネル プロット																																																																			
		コメント：出版バイアスは認められない																																																																	
その他の解析		コメント：																																																																	
メタリ グ レ ッ シ ョ ン																																																																			
感度分析																																																																			

【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																																											
P	早期乳癌 乳房部分切除後			I	寡分割照射																																																																																								
C	通常分割照射			O	7. 晩期有害事象の悪化(晩期肺毒性)																																																																																								
研究デザイン		RCT		文献数	5																																																																																								
コード		Whelan 2002, STARTA 2013, STARTB 2013, Shaitelman 2018, Wang 2020																																																																																											
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																																																								
効果指標		リスク比		統合値	0.96 (0.68-1.37) P = 0.82																																																																																								
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Shaitelman 2018</td><td>0</td><td>97</td><td>0</td><td>108</td><td></td><td>Not estimable</td><td></td></tr><tr><td>Wang 2020</td><td>27</td><td>365</td><td>32</td><td>363</td><td>51.3%</td><td>0.84 [0.51, 1.37]</td><td></td></tr><tr><td>STARTA 2013</td><td>17</td><td>1487</td><td>6</td><td>749</td><td>14.4%</td><td>1.43 [0.57, 3.60]</td><td></td></tr><tr><td>STARTB 2013</td><td>19</td><td>1109</td><td>19</td><td>1105</td><td>31.1%</td><td>1.00 [0.53, 1.87]</td><td></td></tr><tr><td>Whelan 2002</td><td>2</td><td>622</td><td>2</td><td>612</td><td>3.2%</td><td>0.98 [0.14, 6.96]</td><td></td></tr><tr><td colspan="2">Total (95% CI)</td><td colspan="2">3680</td><td colspan="2">2937</td><td>100.0%</td><td>0.96 [0.68, 1.37]</td><td></td></tr><tr><td colspan="2">Total events</td><td colspan="2">65</td><td colspan="2">59</td><td colspan="2"></td><td></td></tr><tr><td colspan="8">Heterogeneity: Tau² = 0.00; Chi² = 1.01, df = 3 (P = 0.80); I² = 0%</td></tr><tr><td colspan="8">Test for overall effect: Z = 0.22 (P = 0.82)</td></tr></tbody></table>				Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	IV, Random, 95% CI	Shaitelman 2018	0	97	0	108		Not estimable		Wang 2020	27	365	32	363	51.3%	0.84 [0.51, 1.37]		STARTA 2013	17	1487	6	749	14.4%	1.43 [0.57, 3.60]		STARTB 2013	19	1109	19	1105	31.1%	1.00 [0.53, 1.87]		Whelan 2002	2	622	2	612	3.2%	0.98 [0.14, 6.96]		Total (95% CI)		3680		2937		100.0%	0.96 [0.68, 1.37]		Total events		65		59					Heterogeneity: Tau ² = 0.00; Chi ² = 1.01, df = 3 (P = 0.80); I ² = 0%								Test for overall effect: Z = 0.22 (P = 0.82)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																						
	Events	Total	Events	Total		IV, Random, 95% CI	IV, Random, 95% CI																																																																																						
Shaitelman 2018	0	97	0	108		Not estimable																																																																																							
Wang 2020	27	365	32	363	51.3%	0.84 [0.51, 1.37]																																																																																							
STARTA 2013	17	1487	6	749	14.4%	1.43 [0.57, 3.60]																																																																																							
STARTB 2013	19	1109	19	1105	31.1%	1.00 [0.53, 1.87]																																																																																							
Whelan 2002	2	622	2	612	3.2%	0.98 [0.14, 6.96]																																																																																							
Total (95% CI)		3680		2937		100.0%	0.96 [0.68, 1.37]																																																																																						
Total events		65		59																																																																																									
Heterogeneity: Tau ² = 0.00; Chi ² = 1.01, df = 3 (P = 0.80); I ² = 0%																																																																																													
Test for overall effect: Z = 0.22 (P = 0.82)																																																																																													
		イベントの頻度が低い。寡分割照射群と通常分割照射群で差は検出されなかった。																																																																																											
ファンネル プロット																																																																																													
		コメント：出版バイアスは認められない																																																																																											
その他の解析		コメント：																																																																																											
メタリ レッシ ョ ン																																																																																													
感度分析																																																																																													





【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																																																				
P	早期乳癌 乳房部分切除後			I	寡分割照射																																																																																																	
C	通常分割照射			O	7. 晩期有害事象の悪化(乳房硬結)																																																																																																	
研究デザイン		RCT		文献数	7																																																																																																	
コード		START A2013, START B2013, Shaitelman 2018, Ofersen2020, Wang 2020, Whelan 2010, Yornold 2005																																																																																																				
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																																																																	
効果指標		リスク比		統合値	0.92 (0.83-1.02) P = 0.10																																																																																																	
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>Risk Ratio IV, Random, 95% CI</th></tr></thead><tbody><tr><td>STARTA 2013</td><td>260</td><td>1244</td><td>142</td><td>616</td><td>33.0%</td><td>0.91 [0.76, 1.09]</td><td rowspan="7"></td></tr><tr><td>STARTB 2013</td><td>129</td><td>1006</td><td>153</td><td>1003</td><td>22.7%</td><td>0.84 [0.68, 1.04]</td></tr><tr><td>Yornold 2005</td><td>163</td><td>535</td><td>77</td><td>271</td><td>20.6%</td><td>1.07 [0.85, 1.35]</td></tr><tr><td>Ofersen 2020</td><td>84</td><td>825</td><td>105</td><td>812</td><td>14.7%</td><td>0.79 [0.60, 1.03]</td></tr><tr><td>Wang 2020</td><td>27</td><td>365</td><td>28</td><td>363</td><td>4.2%</td><td>0.96 [0.58, 1.59]</td></tr><tr><td>Whelan 2010</td><td>28</td><td>235</td><td>23</td><td>220</td><td>4.0%</td><td>1.14 [0.68, 1.92]</td></tr><tr><td>Shaitelman 2018</td><td>6</td><td>97</td><td>5</td><td>108</td><td>0.8%</td><td>1.34 [0.42, 4.24]</td></tr><tr><td colspan="2">Total (95% CI)</td><td colspan="2">4307</td><td colspan="2">3393</td><td>100.0%</td><td>0.92 [0.83, 1.02]</td></tr><tr><td colspan="2">Total events</td><td colspan="2">697</td><td colspan="2">533</td><td colspan="2"></td></tr><tr><td colspan="2">Heterogeneity: Tau² = 0.00; Chi² = 4.77, df = 6 (P = 0.57); I² = 0%</td><td colspan="4"></td><td colspan="2"></td></tr><tr><td colspan="2">Test for overall effect: Z = 1.64 (P = 0.10)</td><td colspan="4"></td><td colspan="2"></td></tr></tbody></table>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	STARTA 2013	260	1244	142	616	33.0%	0.91 [0.76, 1.09]		STARTB 2013	129	1006	153	1003	22.7%	0.84 [0.68, 1.04]	Yornold 2005	163	535	77	271	20.6%	1.07 [0.85, 1.35]	Ofersen 2020	84	825	105	812	14.7%	0.79 [0.60, 1.03]	Wang 2020	27	365	28	363	4.2%	0.96 [0.58, 1.59]	Whelan 2010	28	235	23	220	4.0%	1.14 [0.68, 1.92]	Shaitelman 2018	6	97	5	108	0.8%	1.34 [0.42, 4.24]	Total (95% CI)		4307		3393		100.0%	0.92 [0.83, 1.02]	Total events		697		533				Heterogeneity: Tau² = 0.00; Chi² = 4.77, df = 6 (P = 0.57); I² = 0%								Test for overall effect: Z = 1.64 (P = 0.10)							
		Study or Subgroup	Experimental		Control			Weight	Risk Ratio																																																																																													
Events	Total		Events	Total	IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI																																																																																																
STARTA 2013	260	1244	142	616	33.0%	0.91 [0.76, 1.09]																																																																																																
STARTB 2013	129	1006	153	1003	22.7%	0.84 [0.68, 1.04]																																																																																																
Yornold 2005	163	535	77	271	20.6%	1.07 [0.85, 1.35]																																																																																																
Ofersen 2020	84	825	105	812	14.7%	0.79 [0.60, 1.03]																																																																																																
Wang 2020	27	365	28	363	4.2%	0.96 [0.58, 1.59]																																																																																																
Whelan 2010	28	235	23	220	4.0%	1.14 [0.68, 1.92]																																																																																																
Shaitelman 2018	6	97	5	108	0.8%	1.34 [0.42, 4.24]																																																																																																
Total (95% CI)		4307		3393		100.0%	0.92 [0.83, 1.02]																																																																																															
Total events		697		533																																																																																																		
Heterogeneity: Tau² = 0.00; Chi² = 4.77, df = 6 (P = 0.57); I² = 0%																																																																																																						
Test for overall effect: Z = 1.64 (P = 0.10)																																																																																																						
寡分割照射群で硬結の頻度がやや低い報告が多かったが、全体でも有意差とはならなかった。																																																																																																						
ファンネル プロット																																																																																																						
		コメント：出版バイアスは認められない																																																																																																				
その他の解析		コメント：																																																																																																				
メタリ グ レ ッ シ ョ ン																																																																																																						
感度分析																																																																																																						





【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																													
P	早期乳癌 乳房部分切除後		I	寡分割照射																																																																											
C	通常分割照射		O	7. 晩期有害事象の悪化(毛細血管拡張)																																																																											
研究デザイン		RCT		文献数	5																																																																										
コード		START A2013, START B2013, Shaitelman 2018, Ofersen 2020, Yornold 2005																																																																													
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																																										
効果指標		リスク比		統合値	0.86 (0.67-1.12) P = 0.82																																																																										
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Ofersen 2020</td><td>75</td><td>734</td><td>67</td><td>718</td><td>27.9%</td><td>1.10 [0.80, 1.50]</td><td rowspan="5"></td></tr><tr><td>Yornold 2005</td><td>61</td><td>535</td><td>37</td><td>271</td><td>23.4%</td><td>0.84 [0.57, 1.22]</td></tr><tr><td>STARTA 2013</td><td>61</td><td>1456</td><td>42</td><td>730</td><td>23.3%</td><td>0.73 [0.50, 1.07]</td></tr><tr><td>STARTB 2013</td><td>34</td><td>1094</td><td>52</td><td>1081</td><td>20.9%</td><td>0.65 [0.42, 0.99]</td></tr><tr><td>Shaitelman 2018</td><td>8</td><td>97</td><td>4</td><td>108</td><td>4.5%</td><td>2.23 [0.69, 7.16]</td></tr><tr><td colspan="2">Total (95% CI)</td><td colspan="2">3916</td><td colspan="2">2908</td><td>100.0%</td><td>0.86 [0.67, 1.12]</td></tr><tr><td colspan="2">Total events</td><td colspan="2">239</td><td colspan="2">202</td><td colspan="2"></td></tr><tr><td colspan="8">Heterogeneity: Tau² = 0.04; Chi² = 7.32, df = 4 (P = 0.12); I² = 45% Test for overall effect: Z = 1.09 (P = 0.27)</td></tr></tbody></table> 寡分割照射群で毛細血管拡張の頻度がやや低い報告があったが、全体では有意差とはならなかった。				Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	IV, Random, 95% CI	Ofersen 2020	75	734	67	718	27.9%	1.10 [0.80, 1.50]		Yornold 2005	61	535	37	271	23.4%	0.84 [0.57, 1.22]	STARTA 2013	61	1456	42	730	23.3%	0.73 [0.50, 1.07]	STARTB 2013	34	1094	52	1081	20.9%	0.65 [0.42, 0.99]	Shaitelman 2018	8	97	4	108	4.5%	2.23 [0.69, 7.16]	Total (95% CI)		3916		2908		100.0%	0.86 [0.67, 1.12]	Total events		239		202				Heterogeneity: Tau ² = 0.04; Chi ² = 7.32, df = 4 (P = 0.12); I ² = 45% Test for overall effect: Z = 1.09 (P = 0.27)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																								
	Events	Total	Events	Total		IV, Random, 95% CI	IV, Random, 95% CI																																																																								
Ofersen 2020	75	734	67	718	27.9%	1.10 [0.80, 1.50]																																																																									
Yornold 2005	61	535	37	271	23.4%	0.84 [0.57, 1.22]																																																																									
STARTA 2013	61	1456	42	730	23.3%	0.73 [0.50, 1.07]																																																																									
STARTB 2013	34	1094	52	1081	20.9%	0.65 [0.42, 0.99]																																																																									
Shaitelman 2018	8	97	4	108	4.5%	2.23 [0.69, 7.16]																																																																									
Total (95% CI)		3916		2908		100.0%	0.86 [0.67, 1.12]																																																																								
Total events		239		202																																																																											
Heterogeneity: Tau ² = 0.04; Chi ² = 7.32, df = 4 (P = 0.12); I ² = 45% Test for overall effect: Z = 1.09 (P = 0.27)																																																																															
ファンネル プロット		コメント：出版バイアスは認められない																																																																													
その他の解析		コメント：																																																																													
メタリ グ レ ッ シ ョ ン																																																																															
感度分析																																																																															

【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																																							
P	早期乳癌 乳房部分切除後			I	寡分割照射																																																																																				
C	通常分割照射			O	7. 晩期有害事象の悪化(乳房浮腫)																																																																																				
研究デザイン		RCT		文献数	5																																																																																				
コード		START A2013, START B2013, Shaitelman 2018, Ofersen 2020, Yornold 2005																																																																																							
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																																																				
効果指標		リスク比		統合値	0.74 (0.51-1.07) P = 0.11																																																																																				
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>Risk Ratio IV, Random, 95% CI</th></tr></thead><tbody><tr><td>STARTA 2013</td><td>110</td><td>1244</td><td>78</td><td>616</td><td>29.4%</td><td>0.70 [0.53, 0.92]</td><td rowspan="5"></td></tr><tr><td>STARTB 2013</td><td>49</td><td>1006</td><td>86</td><td>1003</td><td>27.0%</td><td>0.57 [0.40, 0.80]</td></tr><tr><td>Yornold 2005</td><td>83</td><td>535</td><td>34</td><td>271</td><td>25.9%</td><td>1.24 [0.85, 1.79]</td></tr><tr><td>Ofersen 2020</td><td>7</td><td>734</td><td>7</td><td>718</td><td>9.2%</td><td>0.98 [0.34, 2.77]</td></tr><tr><td>Shaitelman 2018</td><td>4</td><td>108</td><td>11</td><td>97</td><td>8.4%</td><td>0.33 [0.11, 0.99]</td></tr><tr><td colspan="2">Total (95% CI)</td><td colspan="2">3627</td><td colspan="2">2705</td><td>100.0%</td><td>0.74 [0.51, 1.07]</td><td></td></tr><tr><td colspan="2">Total events</td><td colspan="2">253</td><td colspan="2">216</td><td colspan="2"></td><td></td></tr><tr><td colspan="8">Heterogeneity: Tau² = 0.10; Chi² = 12.19, df = 4 (P = 0.02); I² = 67%</td></tr><tr><td colspan="8">Test for overall effect: Z = 1.59 (P = 0.11)</td></tr></tbody></table> 寡分割照射群で乳房浮腫の頻度が有意に低い試験もあるが、全体では有意差とはならなかった。				Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	STARTA 2013	110	1244	78	616	29.4%	0.70 [0.53, 0.92]		STARTB 2013	49	1006	86	1003	27.0%	0.57 [0.40, 0.80]	Yornold 2005	83	535	34	271	25.9%	1.24 [0.85, 1.79]	Ofersen 2020	7	734	7	718	9.2%	0.98 [0.34, 2.77]	Shaitelman 2018	4	108	11	97	8.4%	0.33 [0.11, 0.99]	Total (95% CI)		3627		2705		100.0%	0.74 [0.51, 1.07]		Total events		253		216					Heterogeneity: Tau² = 0.10; Chi² = 12.19, df = 4 (P = 0.02); I² = 67%								Test for overall effect: Z = 1.59 (P = 0.11)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																		
	Events	Total	Events	Total		IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI																																																																																		
STARTA 2013	110	1244	78	616	29.4%	0.70 [0.53, 0.92]																																																																																			
STARTB 2013	49	1006	86	1003	27.0%	0.57 [0.40, 0.80]																																																																																			
Yornold 2005	83	535	34	271	25.9%	1.24 [0.85, 1.79]																																																																																			
Ofersen 2020	7	734	7	718	9.2%	0.98 [0.34, 2.77]																																																																																			
Shaitelman 2018	4	108	11	97	8.4%	0.33 [0.11, 0.99]																																																																																			
Total (95% CI)		3627		2705		100.0%	0.74 [0.51, 1.07]																																																																																		
Total events		253		216																																																																																					
Heterogeneity: Tau² = 0.10; Chi² = 12.19, df = 4 (P = 0.02); I² = 67%																																																																																									
Test for overall effect: Z = 1.59 (P = 0.11)																																																																																									
ファンネル プロット		 コメント：出版バイアスは認められない																																																																																							
その他の解析		コメント：																																																																																							
メタリ グ レ ッ シ ョ ン																																																																																									
感度分析																																																																																									





【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																											
P	早期乳癌 乳房部分切除後			I	寡分割照射																																																																								
C	通常分割照射			O	7. 晩期有害事象の悪化(乳房委縮)																																																																								
研究デザイン		RCT		文献数	4																																																																								
コード		START A2013, START B2013, Shaitelman 2018, Yornold 2005																																																																											
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																																								
効果指標		リスク比		統合値	0.90 (0.83-0.98) P = 0.02																																																																								
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th rowspan="2">Risk Ratio IV, Random, 95% CI</th><th rowspan="2">Risk Ratio IV, Random, 95% CI</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th></tr></thead><tbody><tr><td>Yornold 2005</td><td>272</td><td>535</td><td>147</td><td>271</td><td>38.4%</td><td>0.94 [0.82, 1.08]</td><td rowspan="5"></td></tr><tr><td>STARTA 2013</td><td>308</td><td>1244</td><td>165</td><td>616</td><td>27.5%</td><td>0.92 [0.79, 1.09]</td></tr><tr><td>STARTB 2013</td><td>221</td><td>1006</td><td>256</td><td>1003</td><td>29.4%</td><td>0.86 [0.74, 1.01]</td></tr><tr><td>Shaitelman 2018</td><td>29</td><td>97</td><td>40</td><td>108</td><td>4.7%</td><td>0.81 [0.55, 1.19]</td></tr><tr><td>Total (95% CI)</td><td></td><td>2882</td><td></td><td>1998</td><td>100.0%</td><td>0.90 [0.83, 0.98]</td></tr><tr><td colspan="2">Total events</td><td>830</td><td></td><td>608</td><td></td><td></td><td></td></tr><tr><td colspan="7">Heterogeneity: Tau² = 0.00; Chi² = 1.03, df = 3 (P = 0.79); I² = 0%</td><td></td></tr><tr><td colspan="7">Test for overall effect: Z = 2.32 (P = 0.02)</td><td></td></tr></tbody></table>				Study or Subgroup	Experimental		Control		Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	Events	Total	Events	Total	Yornold 2005	272	535	147	271	38.4%	0.94 [0.82, 1.08]		STARTA 2013	308	1244	165	616	27.5%	0.92 [0.79, 1.09]	STARTB 2013	221	1006	256	1003	29.4%	0.86 [0.74, 1.01]	Shaitelman 2018	29	97	40	108	4.7%	0.81 [0.55, 1.19]	Total (95% CI)		2882		1998	100.0%	0.90 [0.83, 0.98]	Total events		830		608				Heterogeneity: Tau² = 0.00; Chi² = 1.03, df = 3 (P = 0.79); I² = 0%								Test for overall effect: Z = 2.32 (P = 0.02)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI																																																																					
	Events	Total	Events	Total																																																																									
Yornold 2005	272	535	147	271	38.4%	0.94 [0.82, 1.08]																																																																							
STARTA 2013	308	1244	165	616	27.5%	0.92 [0.79, 1.09]																																																																							
STARTB 2013	221	1006	256	1003	29.4%	0.86 [0.74, 1.01]																																																																							
Shaitelman 2018	29	97	40	108	4.7%	0.81 [0.55, 1.19]																																																																							
Total (95% CI)		2882		1998	100.0%	0.90 [0.83, 0.98]																																																																							
Total events		830		608																																																																									
Heterogeneity: Tau² = 0.00; Chi² = 1.03, df = 3 (P = 0.79); I² = 0%																																																																													
Test for overall effect: Z = 2.32 (P = 0.02)																																																																													
		寡分割照射群で乳房委縮が軽微な傾向があり、有意差が検出された。																																																																											
ファンネル プロット																																																																													
		コメント：出版バイアスは認められない																																																																											
その他の解析		コメント：																																																																											
メタリグ レシヨ ン																																																																													
感度分析																																																																													

【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																							
P	早期乳癌 乳房部分切除後		I	寡分割照射																																																																					
C	通常分割照射		O	7. 晩期有害事象の悪化(乳房痛)																																																																					
研究デザイン		RCT		文献数	3																																																																				
コード		Shaitelman 2018, Ofersen 2020, Wang 2020																																																																							
モデル		ランダム効果モデル		方法	Inverse-Variance法																																																																				
効果指標		リスク比		統合値	0.75 (0.54-1.05) P = 0.09																																																																				
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>Risk Ratio IV, Random, 95% CI</th></tr></thead><tbody><tr><td>Ofersen 2020</td><td>30</td><td>825</td><td>46</td><td>812</td><td>54.3%</td><td>0.64 [0.41, 1.01]</td><td rowspan="3"></td></tr><tr><td>Shaitelman 2018</td><td>9</td><td>100</td><td>12</td><td>111</td><td>16.3%</td><td>0.83 [0.37, 1.89]</td></tr><tr><td>Wang 2020</td><td>19</td><td>365</td><td>20</td><td>363</td><td>29.4%</td><td>0.94 [0.51, 1.74]</td></tr><tr><td colspan="2">Total (95% CI)</td><td colspan="2">1290</td><td colspan="2">1286</td><td>100.0%</td><td>0.75 [0.54, 1.05]</td></tr><tr><td colspan="2">Total events</td><td colspan="2">58</td><td colspan="2">78</td><td colspan="2"></td></tr><tr><td colspan="8">Heterogeneity: Tau² = 0.00; Chi² = 1.07, df = 2 (P = 0.59); I² = 0%</td></tr><tr><td colspan="8">Test for overall effect: Z = 1.70 (P = 0.09)</td></tr></tbody></table>				Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	Ofersen 2020	30	825	46	812	54.3%	0.64 [0.41, 1.01]		Shaitelman 2018	9	100	12	111	16.3%	0.83 [0.37, 1.89]	Wang 2020	19	365	20	363	29.4%	0.94 [0.51, 1.74]	Total (95% CI)		1290		1286		100.0%	0.75 [0.54, 1.05]	Total events		58		78				Heterogeneity: Tau² = 0.00; Chi² = 1.07, df = 2 (P = 0.59); I² = 0%								Test for overall effect: Z = 1.70 (P = 0.09)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																		
	Events	Total	Events	Total		IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI																																																																		
Ofersen 2020	30	825	46	812	54.3%	0.64 [0.41, 1.01]																																																																			
Shaitelman 2018	9	100	12	111	16.3%	0.83 [0.37, 1.89]																																																																			
Wang 2020	19	365	20	363	29.4%	0.94 [0.51, 1.74]																																																																			
Total (95% CI)		1290		1286		100.0%	0.75 [0.54, 1.05]																																																																		
Total events		58		78																																																																					
Heterogeneity: Tau² = 0.00; Chi² = 1.07, df = 2 (P = 0.59); I² = 0%																																																																									
Test for overall effect: Z = 1.70 (P = 0.09)																																																																									
		寡分割照射群で乳房痛の頻度がやや低い報告があったが、全体では有意差とはなかった。																																																																							
ファンネル プロット																																																																									
		コメント：出版バイアスは認められない																																																																							
その他の解析		コメント：																																																																							
メタリ グ レ ッ シ ョ ン																																																																									
感度分析																																																																									

【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																									
P	早期乳癌 乳房部分切除後	I	寡分割照射																																																																								
C	通常分割照射	O	7. 晩期有害事象の悪化(肋骨骨折)																																																																								
研究デザイン		RCT	文献数	3																																																																							
コード		Whelan 2002, START A 2013, START B 2013																																																																									
モデル		ランダム効果モデル	方法	Inverse-Variance法																																																																							
効果指標		リスク比	統合値	1.43 (0.85-2.39) P = 0.09																																																																							
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>Risk Ratio IV, Random, 95% CI</th></tr></thead><tbody><tr><td>STARTA 2013</td><td>17</td><td>1487</td><td>5</td><td>749</td><td>27.0%</td><td>1.71 [0.63, 4.62]</td><td rowspan="3"></td></tr><tr><td>STARTB 2013</td><td>24</td><td>1110</td><td>17</td><td>1105</td><td>70.4%</td><td>1.41 [0.76, 2.60]</td></tr><tr><td>Whelan 2002</td><td>0</td><td>622</td><td>1</td><td>612</td><td>2.6%</td><td>0.33 [0.01, 8.04]</td></tr><tr><td colspan="2">Total (95% CI)</td><td colspan="2">3219</td><td colspan="2">2466</td><td>100.0%</td><td>1.43 [0.85, 2.39]</td><td></td></tr><tr><td colspan="2">Total events</td><td colspan="2">41</td><td colspan="2">23</td><td colspan="2"></td><td></td></tr><tr><td colspan="8">Heterogeneity: Tau² = 0.00; Chi² = 0.94, df = 2 (P = 0.62); I² = 0%</td></tr><tr><td colspan="8">Test for overall effect: Z = 1.35 (P = 0.18)</td></tr></tbody></table>				Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	STARTA 2013	17	1487	5	749	27.0%	1.71 [0.63, 4.62]		STARTB 2013	24	1110	17	1105	70.4%	1.41 [0.76, 2.60]	Whelan 2002	0	622	1	612	2.6%	0.33 [0.01, 8.04]	Total (95% CI)		3219		2466		100.0%	1.43 [0.85, 2.39]		Total events		41		23					Heterogeneity: Tau² = 0.00; Chi² = 0.94, df = 2 (P = 0.62); I² = 0%								Test for overall effect: Z = 1.35 (P = 0.18)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																				
	Events	Total	Events	Total		IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI																																																																				
STARTA 2013	17	1487	5	749	27.0%	1.71 [0.63, 4.62]																																																																					
STARTB 2013	24	1110	17	1105	70.4%	1.41 [0.76, 2.60]																																																																					
Whelan 2002	0	622	1	612	2.6%	0.33 [0.01, 8.04]																																																																					
Total (95% CI)		3219		2466		100.0%	1.43 [0.85, 2.39]																																																																				
Total events		41		23																																																																							
Heterogeneity: Tau² = 0.00; Chi² = 0.94, df = 2 (P = 0.62); I² = 0%																																																																											
Test for overall effect: Z = 1.35 (P = 0.18)																																																																											
		イベントの頻度が低い。寡分割照射群と通常分割照射群で差は検出されなかった。																																																																									
ファンネル プロット																																																																											
		コメント：出版バイアスは認められない																																																																									
その他の解析				コメント：																																																																							
メタリグ レシヨ ン																																																																											
感度分析																																																																											

【SR-10 メタアナリシス】

CQ		全乳房照射において通常分割照射と同等の治療として寡分割照射は勧められるか？																																																																							
P	早期乳癌 乳房部分切除後	I	寡分割照射																																																																						
C	通常分割照射	O	7. 晩期有害事象の悪化(虚血性心疾患)																																																																						
研究デザイン		RCT	文献数	3																																																																					
コード		START A 2013, START B 2013, Wang 2020																																																																							
モデル		ランダム効果モデル	方法	Inverse-Variance法																																																																					
効果指標		リスク比	統合値	0.78 (0.50-1.20) P = 0.25																																																																					
フォレスト プロット		<table><thead><tr><th rowspan="2">Study or Subgroup</th><th colspan="2">Experimental</th><th colspan="2">Control</th><th rowspan="2">Weight</th><th colspan="2">Risk Ratio</th></tr><tr><th>Events</th><th>Total</th><th>Events</th><th>Total</th><th>IV, Random, 95% CI</th><th>Risk Ratio IV, Random, 95% CI</th></tr></thead><tbody><tr><td>STARTA 2013</td><td>19</td><td>1487</td><td>14</td><td>749</td><td>39.8%</td><td>0.68 [0.34, 1.36]</td><td rowspan="3"></td></tr><tr><td>STARTB 2013</td><td>17</td><td>1110</td><td>23</td><td>1105</td><td>48.4%</td><td>0.74 [0.40, 1.37]</td></tr><tr><td>Wang 2020</td><td>6</td><td>365</td><td>4</td><td>363</td><td>11.8%</td><td>1.49 [0.42, 5.24]</td></tr><tr><td colspan="2">Total (95% CI)</td><td colspan="2">2962</td><td colspan="2">2217</td><td>100.0%</td><td>0.78 [0.50, 1.20]</td></tr><tr><td colspan="2">Total events</td><td colspan="2">42</td><td colspan="2">41</td><td colspan="2"></td></tr><tr><td colspan="2">Heterogeneity: Tau² = 0.00; Chi² = 1.20, df = 2 (P = 0.55); I² = 0%</td><td colspan="6"></td></tr><tr><td colspan="2">Test for overall effect: Z = 1.15 (P = 0.25)</td><td colspan="6"></td></tr></tbody></table>				Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	STARTA 2013	19	1487	14	749	39.8%	0.68 [0.34, 1.36]		STARTB 2013	17	1110	23	1105	48.4%	0.74 [0.40, 1.37]	Wang 2020	6	365	4	363	11.8%	1.49 [0.42, 5.24]	Total (95% CI)		2962		2217		100.0%	0.78 [0.50, 1.20]	Total events		42		41				Heterogeneity: Tau ² = 0.00; Chi ² = 1.20, df = 2 (P = 0.55); I ² = 0%								Test for overall effect: Z = 1.15 (P = 0.25)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																		
	Events	Total	Events	Total		IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI																																																																		
STARTA 2013	19	1487	14	749	39.8%	0.68 [0.34, 1.36]																																																																			
STARTB 2013	17	1110	23	1105	48.4%	0.74 [0.40, 1.37]																																																																			
Wang 2020	6	365	4	363	11.8%	1.49 [0.42, 5.24]																																																																			
Total (95% CI)		2962		2217		100.0%	0.78 [0.50, 1.20]																																																																		
Total events		42		41																																																																					
Heterogeneity: Tau ² = 0.00; Chi ² = 1.20, df = 2 (P = 0.55); I ² = 0%																																																																									
Test for overall effect: Z = 1.15 (P = 0.25)																																																																									
		イベントの頻度が低い。寡分割照射群と通常分割照射群で差は検出されなかった。10年程度の経過観察をしているデータが主だが、観察期間はまだ十分でない可能性がある。																																																																							
ファンネル プロット																																																																									
		コメント：出版バイアスは認められない																																																																							
その他の解析		コメント：																																																																							
メタリ グ レ ッ シ ョ ン																																																																									
感度分析																																																																									